ASXL1 and IDH2 mutations were predominantly identified in patients with AML-MR, whereas NRAS mutations were frequently detected in patients with AML, defining genetic abnormalities in the 2022 WHO. This evidence concerns the gene NRAS and acute myeloid leukemia.